Ovarian Cancer

Primary Cytoreductive Surgery for HGSC Offers Better Survival Than Neoadjuvant Chemotherapy

Primary Cytoreductive Surgery for HGSC Offers Better Survival Than Neoadjuvant Chemotherapy

By

Researchers conducted a retrospective cohort analysis to examine patterns of clinical practice in the management of women with advanced HGSC.

Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

By

The US FDA granted approval based on results from ARIEL3, a randomized clinical trial conducted with 561 eligible cancer patients.

Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters

Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters

By

Researchers hypothesize that ovarian cancer may be X-linked and associated genes may be passed from the paternal grandmother via the father's inherited genetic material.

USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women

USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women

By

An USPSTF updated recommendation statement for ovarian cancer screening recommends against screening for women who are asymptomatic and do not have high-risk hereditary cancer syndrome.

Investigators Examine Link Between Epithelial Ovarian Cancer Risk, Antidepressant Treatment

Investigators Examine Link Between Epithelial Ovarian Cancer Risk, Antidepressant Treatment

Researchers conducted a meta-analysis to examined possible links between antidepressant use and epithelial ovarian cancer, and links between duration and intensity of antidepressant use and risk for epithelial ovarian cancer.

Ovarian, Endometrial Cancer Risk Lower With Long-Term Oral Contraceptive Use

Ovarian, Endometrial Cancer Risk Lower With Long-Term Oral Contraceptive Use

By

Researchers sought to determine if a correlation was present between extended oral contraceptive use and a decreased risk of certain cancers.

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

By

Researchers explored the effectiveness of wearing frozen gloves and socks before and after treatment with PLD to prevent or manage hand-foot syndrome in patients with ovarian cancer.

Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients

1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival compared to those treated with surgery and chemotherapy alone. 2. No difference in grade 3 or 4 adverse side effects were observed between HIPEC and non-HIPEC treated []

Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer

1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average)     Study Rundown: Females with BRCA1 mutations in their germline []

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

By

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

By

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

By

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

By

Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

By

Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

By

A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.

Quality of Life in Ovarian Cancer Not Diminished by Olaparib

Quality of Life in Ovarian Cancer Not Diminished by Olaparib

By

Change in FACT-O TOI score from baseline to 12 months did not differ significantly between maintenance olaparib and placebo.

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

By

Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

By

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

By

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

By

A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

By

A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.

Priority Symptoms Identified in Recurrent Ovarian Cancer

Priority Symptoms Identified in Recurrent Ovarian Cancer

By

There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

By

Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

By

Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

By

A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

By

An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

By

Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

By

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs